|
GB8311018D0
(en)
|
1983-04-22 |
1983-05-25 |
Amersham Int Plc |
Detecting mutations in dna
|
|
US4998617A
(en)
|
1986-09-15 |
1991-03-12 |
Laura Lupton Inc |
Facial cosmetic liquid make up kit
|
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US6270961B1
(en)
|
1987-04-01 |
2001-08-07 |
Hyseq, Inc. |
Methods and apparatus for DNA sequencing and DNA identification
|
|
US5176996A
(en)
|
1988-12-20 |
1993-01-05 |
Baylor College Of Medicine |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
FR2650840B1
(fr)
|
1989-08-11 |
1991-11-29 |
Bertin & Cie |
Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
|
US6004744A
(en)
|
1991-03-05 |
1999-12-21 |
Molecular Tool, Inc. |
Method for determining nucleotide identity through extension of immobilized primer
|
|
US5858659A
(en)
|
1995-11-29 |
1999-01-12 |
Affymetrix, Inc. |
Polymorphism detection
|
|
US5952172A
(en)
|
1993-12-10 |
1999-09-14 |
California Institute Of Technology |
Nucleic acid mediated electron transfer
|
|
US5968740A
(en)
|
1995-07-24 |
1999-10-19 |
Affymetrix, Inc. |
Method of Identifying a Base in a Nucleic Acid
|
|
WO1997040462A2
(en)
|
1996-04-19 |
1997-10-30 |
Spectra Biomedical, Inc. |
Correlating polymorphic forms with multiple phenotypes
|
|
JP2894445B2
(ja)
|
1997-02-12 |
1999-05-24 |
日本たばこ産業株式会社 |
Ｃｅｔｐ活性阻害剤として有効な化合物
|
|
WO1999013108A1
(en)
|
1997-09-10 |
1999-03-18 |
University Of Maryland, Baltimore |
Method of amplifying dna and rna mismatch cleavage products
|
|
US6197786B1
(en)
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
|
EP1554925A1
(en)
|
1999-06-04 |
2005-07-20 |
Consejo Superior de Investigaciones Cientificas |
Food and cosmetic products comprising high oleic high stearic oils
|
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
|
CO5271716A1
(es)
|
1999-11-30 |
2003-04-30 |
Pfizer Prod Inc |
Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
|
|
WO2003015708A2
(en)
|
2001-08-18 |
2003-02-27 |
Myriad Genetics, Inc |
Composition and method for treating hiv infection
|
|
US20060141493A1
(en)
|
2001-11-09 |
2006-06-29 |
Duke University Office Of Science And Technology |
Atherosclerotic phenotype determinative genes and methods for using the same
|
|
US20040180370A1
(en)
|
2003-01-27 |
2004-09-16 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetic diagnosis of alcoholism subtypes
|
|
WO2004082675A1
(en)
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
|
|
TWI494102B
(zh)
|
2003-05-02 |
2015-08-01 |
Japan Tobacco Inc |
包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
|
|
US7276608B2
(en)
|
2003-07-11 |
2007-10-02 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
|
US7326706B2
(en)
|
2003-08-15 |
2008-02-05 |
Bristol-Myers Squibb Company |
Pyrazine modulators of cannabinoid receptors
|
|
WO2005030185A2
(en)
|
2003-09-26 |
2005-04-07 |
Japan Tobacco Inc. |
Method of inhibiting remnant lipoprotein production
|
|
WO2005037199A2
(en)
|
2003-10-10 |
2005-04-28 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
DK1697371T3
(da)
|
2003-12-19 |
2007-09-17 |
Bristol Myers Squibb Co |
Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
|
|
RU2006126122A
(ru)
|
2003-12-19 |
2008-01-27 |
Бристол-Маерс Сквибб Компани (Us) |
Азабициклические гетероциклы как модуляторы каннабиоидного рецептора
|
|
KR20070010151A
(ko)
|
2004-03-30 |
2007-01-22 |
사파이어 세라퓨틱스, 인크. |
성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
|
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
WO2006063828A1
(de)
|
2004-12-18 |
2006-06-22 |
Bayer Healthcare Ag |
4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
|
|
JP2008526783A
(ja)
|
2005-01-05 |
2008-07-24 |
メディキュア・インターナショナル・インコーポレーテッド |
トリグリセリドレベルを調節するための化合物及び方法
|
|
WO2006099142A2
(en)
*
|
2005-03-10 |
2006-09-21 |
The Trustees Of Boston University |
Prognostic method for vascular diseases
|
|
JP2006288279A
(ja)
|
2005-04-11 |
2006-10-26 |
Otsuka Pharmaceut Co Ltd |
出血時間延長傾向判定方法
|
|
CN102757397A
(zh)
|
2005-07-01 |
2012-10-31 |
默沙东公司 |
合成cetp抑制剂的方法
|
|
WO2007048027A2
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
|
US7435849B2
(en)
|
2005-10-31 |
2008-10-14 |
Hoffmann-La Roche Inc. |
Process for the production of acid chlorides
|
|
CA2627599A1
(en)
|
2005-11-08 |
2007-05-18 |
Ranbaxy Laboratories Limited |
Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
|
WO2007071824A1
(en)
*
|
2005-12-20 |
2007-06-28 |
Oy Jurilab Ltd |
Novel genes and markers associated with high-density lipoprotein -cholesterol (hdl-c)
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
WO2008067219A2
(en)
|
2006-11-29 |
2008-06-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
EP1935867A1
(en)
|
2006-12-20 |
2008-06-25 |
F. Hoffmann-La Roche Ag |
Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
|
|
WO2008097976A1
(en)
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
JP5314671B2
(ja)
|
2007-04-25 |
2013-10-16 |
エフ．ホフマン−ラ ロシュ アーゲー |
酸塩化物の新規合成方法
|
|
US20090105124A1
(en)
|
2007-08-23 |
2009-04-23 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
EP2274278B1
(en)
|
2008-04-04 |
2016-08-17 |
F. Hoffmann-La Roche AG |
New process for the preparatiion of cyclohexanecarboxylic acid dericatives
|
|
ES2460900T3
(es)
|
2008-04-04 |
2014-05-14 |
F. Hoffmann-La Roche Ag |
Nuevo procedimiento para la preparación de derivados de ácido ciclohexanocarboxílico mediante el correspondiente derivado ciclohexanocarboxamida
|
|
MX2010013403A
(es)
|
2008-06-17 |
2010-12-22 |
Hoffmann La Roche |
Ester del acido 1-(2-etil-butil)-ciclohexanocarboxilico como un intermediario en la preparacion de amidas farmaceuticamente activas.
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
US20100183598A1
(en)
|
2008-11-12 |
2010-07-22 |
Carolus Therapeutics, Inc. |
Methods of treating cardiovascular disorders
|
|
EP2373344B1
(en)
|
2008-12-08 |
2016-03-30 |
F. Hoffmann-La Roche AG |
Combined drug administration
|
|
NZ624963A
(en)
|
2009-04-29 |
2016-07-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
AR077208A1
(es)
|
2009-06-30 |
2011-08-10 |
Lilly Co Eli |
Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
|
|
US20110004011A1
(en)
|
2009-07-01 |
2011-01-06 |
Declan Costello |
Novel process
|
|
JP2012533560A
(ja)
|
2009-07-15 |
2012-12-27 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
細胞における取り込みが制御可能なペプチド
|
|
WO2011127307A1
(en)
|
2010-04-07 |
2011-10-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cetp expression
|
|
CA2806606A1
(en)
*
|
2010-07-28 |
2012-02-02 |
Institut De Cardiologie De Montreal |
Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
|
|
CN103097345A
(zh)
|
2010-09-16 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
新方法
|
|
MY164729A
(en)
|
2010-11-04 |
2018-01-30 |
Hoffmann La Roche |
A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
|
|
WO2012069087A1
(en)
|
2010-11-25 |
2012-05-31 |
Mediasuccess Gmbh |
Automatic text generation
|
|
BR112013014291A2
(pt)
|
2010-12-08 |
2016-09-20 |
Hoffmann La Roche |
formulação lipossômica de calcetrapib
|
|
JP6054875B2
(ja)
|
2010-12-16 |
2016-12-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ジスルフィドの水素化による芳香族チオール誘導体の調製方法
|
|
WO2012112720A2
(en)
*
|
2011-02-15 |
2012-08-23 |
The Ohio University Research Foundaton |
Methods for predicting cardiovascular risks and responsiveness to statin therapy using snps
|
|
RU2013139701A
(ru)
|
2011-02-17 |
2015-03-27 |
Ф. Хоффманн-Ля Рош Аг |
Способ контролируемой кристаллизации активного фармацевтического ингредиента из состояния переохлажденной жидкости экструзией горячего распада
|
|
JP5980900B2
(ja)
|
2011-04-08 |
2016-08-31 |
ゾラ バイオサイエンシーズ オサケ ユキチュア |
スタチン誘発性筋毒性の高感度検出のためのバイオマーカー
|
|
US9541565B2
(en)
|
2011-04-08 |
2017-01-10 |
Zora Biosciences Oy |
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
WO2012149473A2
(en)
*
|
2011-04-29 |
2012-11-01 |
Children's Hospital & Research Center At Oakland |
Compositions and methods to assess the capacity of hdl to support reverse cholesterol transport
|
|
US20120301439A1
(en)
|
2011-05-24 |
2012-11-29 |
Washington University |
Inhibition of choroidal neovascularization
|
|
US8975438B2
(en)
|
2011-07-13 |
2015-03-10 |
Hoffmann-La Roche Inc. |
Process for the preparation of cyclohexanecarboxylic acid derivatives
|
|
AR089853A1
(es)
|
2012-02-01 |
2014-09-24 |
Boehringer Ingelheim Int |
Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
|
|
NZ628587A
(en)
|
2012-03-06 |
2016-07-29 |
Boehringer Ingelheim Int |
Benzodioxanes in combination with other actives for inhibiting leukotriene production
|
|
HK1202445A1
(en)
|
2012-04-30 |
2015-10-02 |
霍夫曼-拉罗奇有限公司 |
New formulation
|
|
MX351059B
(es)
|
2012-08-17 |
2017-09-29 |
Laboratorios Senosiain S A De C V Star |
Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
|
|
EP2978859B1
(en)
|
2013-03-27 |
2018-06-27 |
F.Hoffmann-La Roche Ag |
Genetic markers for predicting responsiveness to therapy
|
|
EP3082784A1
(en)
|
2013-12-19 |
2016-10-26 |
F.Hoffmann-La Roche Ag |
Cetp modulator for use in the treatment of eye disease
|
|
GB201401617D0
(en)
*
|
2014-01-30 |
2014-03-19 |
Helperby Therapeutics Ltd |
Novel combination and use
|
|
RU2703192C2
(ru)
|
2014-07-30 |
2019-10-15 |
Ф. Хоффманн-Ля Рош Аг |
Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
|
|
US20190070178A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
|
|
CA3108437A1
(en)
|
2018-08-09 |
2020-02-13 |
Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch |
Methods for delaying occurrence of new-onset type 2 diabetes and for slowing progression of and treating type 2 diabetes
|